Carlos J. Díaz Osterman, Ph.D.

Assistant Investigator and Co-Leader, Organoid Core, University of Puerto Rico Comprehensive Cancer Center, Department of Cancer Genetics & Therapeutics, Division of Cancer Biology, San Juan, Puerto Rico | Assistant Professor, ad honorem, University of Puerto Rico Medical Sciences Campus, Department of Biochemistry, San Juan, Puerto Rico


Dr. Carlos Díaz Osterman is an Assistant Investigator of Cancer Biology at the University of Puerto Rico Comprehensive Cancer Center. His work focuses on cancer metabolism, therapy response, and the identification of novel multi-omic signatures predictive of outcomes among Puerto Ricans with cancer. His work has been funded by pilot awards from both the Research Centers in Minority Institutions (RCMI) and U54 Partnerships to Advance Cancer Health Equity (PACHE) programs, as well as the Puerto Rico IDeA Network for Biomedical Research Excellence (PR-INBRE) and the Puerto Rico Science, Technology, and Research Trust.

Dr. Díaz Osterman was awarded his doctoral degree in 2015 following his graduate studies on therapy resistance in pancreatic cancer as part of the NIGMS Initiative for Maximizing Student Development program in the Center for Health Disparities and Molecular Medicine at Loma Linda University School of Medicine. His postdoctoral training was performed under the mentorship of Dr. David D. Schlaepfer at the Moores Cancer Center, University of California, San Diego. This fellowship included further training in therapy resistance mechanisms and was sponsored by the NCI T32 Cancer Therapeutics Training program. He returned to Loma Linda University for a second postdoctoral fellowship focused on prostate cancer disparities. He was recruited to the Ponce Research Institute at Ponce Health Sciences University in Puerto Rico in 2019. During his time in Ponce, Dr. Díaz Osterman mentored over 10 trainees and rotational students, whose work resulted in over 30 trainee-led abstracts and scientific presentations. He joined the University of Puerto Rico Comprehensive Cancer Center’s Cancer Genetics and Therapeutics Department in August 2023.